Competitor Analysis ErbB / Her Receptor Antagonists
Delivery costs do not apply or are included.
Ask a question about this product
Competitor Analysis ErbB / Her Receptor Antagonists
Product description
The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis ErbB / Her Receptor Antagonists
Table of Contents
- Sales of Small Molecules Inhibitors of the ErbB/Her Receptor Family
- Sales of Antibodies Targeting ErbB/Her Receptors
1) Small Molecules Targeting the ErbB/Her Receptor Family
a) Selective EGF-R Tyrosine Kinase (TK) Inhibitors
- Tarceva Pipeline
- Iressa Pipeline
- Pipeline of Other EGF-R Selective TK Inhibitors
b) Selective Her2 (ErbB2) TK Inhibitors
c) Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
- Tykerb Pipeline
- Pipeline of Other Dual EGF-R (ErbB1) and Her2 (ErbB2) TK Inhibitors
d) Pan-Her (EGF-R, Her2 and Her4) / pan-Erb (ErbB1, ErbB2, ErbB4) TK Inhibitors
- Gilotrif Pipeline
- Neratinib Pipeline
- Dacomitinb Pipeline
- Poziotinib Pipeline
- Pipeline of Other Pan-Her Tk Inhibitors
e) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) Inhibition
f) Multi-Target TK Inhibitors incl. EGF-R (ErbB1) and Her2 (ErbB2) Inhibition
2) Biologics (Cells, Proteins, RNA) Targeting the ErbB/Her Receptor Family
3) Vaccines Targeting the ErbB/Her Receptor Family
a) EGF-R (ErbB1) Vaccines
b) Her2 (ErbB2) Vaccines
c) Her3 (ErbB3) Vaccines
4) Antibodies Targeting the ErbB/Her Receptor Family
a) Selective EGF-R (ErbB1) Antibodies
- Erbitux Pipeline
- Vectibix Pipeline
- Nimotuzumab Pipeline
- Pipeline of Other Selective EGF-R (ErbB1) Antibodies
- Biosimilar Cetuximab Pipeline
- Biosimilar Panitumumab Pipeline
b) Selective Her2 (ErbB2) Antibodies
- Herceptin Pipeline
- Perjeta Pipeline
- Kadcyla Pipeline
- Pipeline of Other Selective Her2 (ErbB2) Antibodies
- Biosimilar Trastuzumab Pipeline
c) Selective Her3 (ErbB3) Antibodies
d) Dual and Pan ErbB / Her Antibodies
e) Dual Target Antibodies incl. ErbB/Her Receptor Antagonism
5) Corporate ErbB/Her Receptor Antagonist R&D Pipelines